AIG
ACRS icon

American International Group’s Aclaris Therapeutics ACRS Stock Holding History

American International Group’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-34,229
Closed -$42.4K – 38
2024
Q1 		$42.4K Sell
34,229
-294
-0.9% -$351 ﹤0.01% 2820
2023
Q4 		$36.2K Sell
34,523
-138
-0.4% -$421 ﹤0.01% 2878
2023
Q3 		$237K Buy
34,661
+1,232
+4% +$10.5K ﹤0.01% 2033
2023
Q2 		$347K Buy
33,429
+2,249
+7% +$20.3K ﹤0.01% 1868
2023
Q1 		$252K Buy
31,180
+620
+2% +$7.87K ﹤0.01% 1987
2022
Q4 		$481K Sell
30,560
-110
-0.4% -$1.77K ﹤0.01% 1612
2022
Q3 		$483K Buy
30,670
+2,669
+10% +$42K ﹤0.01% 1595
2022
Q2 		$391K Buy
28,001
+2,678
+11% +$37.5K ﹤0.01% 1774
2022
Q1 		$437K Sell
25,323
-1,783
-7% -$24.3K ﹤0.01% 1797
2021
Q4 		$394K Sell
27,106
-811
-3% -$12.3K ﹤0.01% 1960
2021
Q3 		$503K Buy
27,917
+3,589
+15% +$57.5K ﹤0.01% 1853
2021
Q2 		$427 Buy
+24,328
New +$553K ﹤0.01% 2025
2020
Q2 		– Sell
-18,241
Closed -$19K – 3105
2020
Q1 		$19K Sell
18,241
-1,053
-5% -$1.43K ﹤0.01% 2934
2019
Q4 		$36K Sell
19,294
-163
-0.8% -$270 ﹤0.01% 2949
2019
Q3 		$21K Sell
19,457
-135
-0.7% -$191 ﹤0.01% 3019
2019
Q2 		$43K Sell
19,592
-2,984
-13% -$16.3K ﹤0.01% 2975
2019
Q1 		$135K Sell
22,576
-731
-3% -$4.85K ﹤0.01% 2438
2018
Q4 		$172K Buy
23,307
+5,575
+31% +$57.5K ﹤0.01% 2268
2018
Q3 		$257K Buy
17,732
+318
+2% +$5.45K ﹤0.01% 2276
2018
Q2 		$348K Buy
17,414
+2,554
+17% +$47.2K ﹤0.01% 2050
2018
Q1 		$260K Sell
14,860
-799
-5% -$16.9K ﹤0.01% 2124
2017
Q4 		$386K Buy
15,659
+2,147
+16% +$52.3K ﹤0.01% 1931
2017
Q3 		$349K Buy
13,512
+1,010
+8% +$27.1K ﹤0.01% 1968
2017
Q2 		$339K Buy
12,502
+5,698
+84% +$155K ﹤0.01% 1954
2017
Q1 		$203K Buy
6,804
+1,623
+31% +$46.8K ﹤0.01% 2175
2016
Q4 		$141K Sell
5,181
-14
-0.3% -$357 ﹤0.01% 2394
2016
Q3 		$133K Buy
5,195
+7
+0.1% +$149 ﹤0.01% 2439
2016
Q2 		$95.8K Buy
5,188
+1,867
+56% +$37K ﹤0.01% 2634
2016
Q1 		$63K Buy
+3,321
New +$63.5K ﹤0.01% 3735

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

American International Group's ACRS Position: Q2 2024 in Review

American International Group sold out of Aclaris Therapeutics (ACRS) in Q2 2024, closing a stake of 34,229 shares — an estimated $42.4K sold.

American International Group first reported a position in ACRS in Q1 2016 and held it in 29 quarters. The position peaked at $503K in Q3 2021. 98 funds tracked by Wall St. Rank hold ACRS as of Q2 2024.

  • American International Group reported no remaining Aclaris Therapeutics position as of Q2 2024 after selling out during the quarter.
  • American International Group sold 34,229 Aclaris Therapeutics shares in Q2 2024, an estimated $42.4K.
  • American International Group first reported a position in Aclaris Therapeutics in Q1 2016 and held it in 29 quarters.
  • American International Group's Aclaris Therapeutics position peaked at $503K in Q3 2021.
  • 98 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2024.

Based on American International Group's 13F filing for Q2 2024, filed 13 Aug 2024.